Cargando…

A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome

Bladder cancer is a biologically heterogeneous disease with variable clinical presentations, outcomes and responses to therapy. Thus, the clinical utility of single biomarkers for the detection and prediction of biological behavior of bladder cancer is limited. We have previously identified and vali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Runpu, Pagano, Ian, Sun, Yijun, Murakami, Kaoru, Goodison, Steve, Vairavan, Ramanathan, Tahsin, Malak, Black, Peter C., Rosser, Charles J., Furuya, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332739/ https://www.ncbi.nlm.nih.gov/pubmed/35892512 http://dx.doi.org/10.3390/diagnostics12081801

Ejemplares similares

Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model
por: Murakami, Kaoru, et al.
Publicado: (2021)

Diagnostic performance of Oncuria™, a urinalysis test for bladder cancer
por: Hirasawa, Yosuke, et al.
Publicado: (2021)

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
por: Murakami, Kaoru, et al.
Publicado: (2022)

PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity
por: Furuya, Hideki, et al.
Publicado: (2022)

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
por: Zhang, Ge, et al.
Publicado: (2014)

Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer
por: Murakami, Kaoru, et al.
Publicado: (2023)

Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer—A Pilot Study
por: Murakami, Kaoru, et al.
Publicado: (2022)

Identifying Significantly Perturbed Subnetworks in Cancer Using Multiple Protein–Protein Interaction Networks
por: Yang, Le, et al.
Publicado: (2023)

A multiplex immunoassay for the non-invasive detection of bladder cancer
por: Shimizu, Yoshiko, et al.
Publicado: (2016)

Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2020)

Computational approach for deriving cancer progression roadmaps from static sample data
por: Sun, Yijun, et al.
Publicado: (2017)

Bladder Cancer Detection and Monitoring: Assessment of Urine- and Blood-Based Marker Tests
por: Goodison, Steve, et al.
Publicado: (2013)

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer
por: Masuda, Norihiko, et al.
Publicado: (2018)

A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort
por: Goodison, Steve, et al.
Publicado: (2016)

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
por: Furuya, Hideki, et al.
Publicado: (2019)

Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
por: Furuya, Hideki, et al.
Publicado: (2023)

A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer
por: Goodison, Steve, et al.
Publicado: (2012)

Simultaneous multi-analyte urinary protein assay for bladder cancer detection
por: Rosser, Charles J, et al.
Publicado: (2014)

Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation
por: Peres, Rafael, et al.
Publicado: (2016)

CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer
por: Urquidi, Virginia, et al.
Publicado: (2012)

IL-8 as a urinary biomarker for the detection of bladder cancer
por: Urquidi, Virginia, et al.
Publicado: (2012)

microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes
por: Pardini, Barbara, et al.
Publicado: (2018)

A microRNA biomarker panel for the non-invasive detection of bladder cancer
por: Urquidi, Virginia, et al.
Publicado: (2016)

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2014)

Prognostic cancer gene signatures share common regulatory motifs
por: Wang, Ying, et al.
Publicado: (2017)

Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth
por: Miyake, Makito, et al.
Publicado: (2019)

A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer
por: Zhong, Min-Er, et al.
Publicado: (2022)

Computational disease progression modeling can provide insights into cancer evolution
por: Goodison, Steve, et al.
Publicado: (2020)

Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes
por: Li, Huili, et al.
Publicado: (2020)

Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
por: Sjödahl, Gottfrid, et al.
Publicado: (2022)

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers
por: Miyake, Makito, et al.
Publicado: (2013)

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
por: Miyake, Makito, et al.
Publicado: (2013)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

CXCL1 is elevated in the urine of bladder cancer patients
por: Burnier, Andre, et al.
Publicado: (2015)

Cancer progression modeling using static sample data
por: Sun, Yijun, et al.
Publicado: (2014)

Alignment-free comparison of metagenomics sequences via approximate string matching
por: Chen, Jian, et al.
Publicado: (2022)

Realising stratified psychiatry using multidimensional signatures and trajectories
por: Joyce, Dan W., et al.
Publicado: (2017)

Distinct interferon signatures stratify inflammatory and dysimmune myopathies
por: Rigolet, Muriel, et al.
Publicado: (2019)

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients
por: Chan, Owen T.M., et al.
Publicado: (2017)

Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma
por: Zhang, Fan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fek525nmhportjnpg41m5mto9s